SCHEMBL26424200

SCHEMBL26424200

CC(=O)CCC(CP(=O)(CCC(=O)OC(C)(C)C)OCc1ccccc1)C(=O)OCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.44
SYK P43405 1/20 0.39
CETP P11597 3/20 0.38
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 2/20 0.36
XBP1 P17861 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ABCC3 O15438 1/20 0.36
NR1I2 O75469 1/20 0.36
ABCB11 O95342 1/20 0.36
NR3C1 P04150 1/20 0.36
RARG P13631 1/20 0.36
CNR1 P21554 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23710509 0.94 FOLH1 (0.44) FOLH1SYKCETPALDH1A1POLB
SCHEMBL26424221 0.88 FOLH1 (0.46) FOLH1CETPALDH1A1CYP1A2CYP3A4
SCHEMBL26424198 0.87 FOLH1 (0.55) FOLH1CETPALDH1A1
SCHEMBL23705342 0.85 FOLH1 (0.63) FOLH1
SCHEMBL23710443 0.82 FOLH1 (0.46) FOLH1CETPALDH1A1POLB
SCHEMBL23710442 0.81 FOLH1 (0.45) FOLH1CETPALDH1A1POLBMAPT
SCHEMBL23705074 0.81 FOLH1 (0.52) FOLH1CETPALDH1A1
SCHEMBL23710534 0.80 FOLH1 (0.48) FOLH1CETPALDH1A1
SCHEMBL14102848 0.79 FOLH1 (0.51) FOLH1CETPALDH1A1
SCHEMBL6381340 0.78 POLB (0.42) FOLH1SYKPOLBMAPTXBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230128984-A1 BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230128984-A1 BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) SLC10A2, GPBAR1, NR1H4 FOLH1 828/4885SYK 2656/4885CETP 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.